The short answer
Do not add valerian root to selinexor without the cancer team’s review. Selinexor can cause neurological symptoms, and a sedating supplement may make alertness or balance harder to manage; the exact combined effect has not been measured.
What this answer covers
Oral selinexor with valerian root preparations. Current root/rhizome entry is broader than the verified Valeriana officinalis study preparation.
- Supplement or preparation
- Radix et Rhizoma Valerianae
- Medication ingredient
- selinexor
Check the prescribed treatment
This review concerns oral selinexor. Its schedule and combination medicines depend on the cancer treatment plan. The drug can cause low platelets, dizziness or confusion, and other medicines and hydration status may contribute. Keep the complete regimen and monitoring plan under the cancer team’s direction.
Why alertness matters
Selinexor can cause dizziness, confusion and other neurological symptoms. Its product information advises reviewing other medicines and hydration to avoid worsening dizziness or mental-status changes, and using precautions against falls. Report new symptoms rather than assuming they are an expected supplement effect.
What is known about the supplement
Valerian guidance warns about combining it with sedatives. However, a small acute study of a defined Valeriana officinalis extract found no significant psychomotor or cognitive impairment. That null finding does not prove safety during selinexor treatment, and other species or blends are not equivalent.
Review the cause of sleep or pain symptoms
Show the team the exact product and dose, including alcohol, sleep aids, pain medicines and anti-nausea medicines. Do not drive when dizzy or confused, and seek prompt assessment for marked changes in alertness. A dose gap has not been shown to prevent this concern, and cancer treatment should not be adjusted without the team.
Evidence and practical considerations
Side effects & toxicity
A conditional alertness/fall-risk precaution is supported, without proving a specific combined CNS-depression rate.
- Exact scope
- Oral selinexor with valerian root preparations. Current root/rhizome entry is broader than the verified Valeriana officinalis study preparation. with RxNorm 2178390 IN selinexor. Exact current oral product: XPOVIO oral selinexor tablets. Salt, formulation and regimen distinctions explicit.
- Medication form and route
- Oral
What remains uncertain
- No exact co-use study; conditional neurological precaution, not established respiratory depression or a dose-specific additive rate. Small acute V. officinalis null retained; species/preparation must be verified.
Factors that may matter: Exact oral formulation and supplement preparation; Drug exposure versus clinical outcomes; Dose and duration; Platelet count and neurological symptoms.
Read the supporting source summaries
Source 1: Current original prescribing information
dailymed.nlm.nih.gov · Source check Sep 11, 2026
Population: Patients prescribed the exact oral formulation.
Thrombocytopenia and neurological toxicity; clinical CYP3A inhibitor and inducer PK null results.
How this applies: RxNorm 2178390 IN selinexor. Exact current oral product: XPOVIO oral selinexor tablets. Salt, formulation and regimen distinctions explicit.
Exact product source, not a direct study of every supplement. Population, active metabolites and formulation scope retained.
Source 2: Original official botanical guidance
nccih.nih.gov · Source check Sep 11, 2026
Population: Users of valerian root/rhizome preparations.
Possible sleep-inducing effects; avoid combination with sedatives/alcohol.
How this applies: Conditional preparation-specific neurological precaution.
Not exact selinexor co-use; current generic root name does not verify every Valeriana species.
Source 3: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: 10 young healthy volunteers.
No significant subjective or psychomotor/cognitive impairment with tested valerian; diazepam positive control impaired performance.
How this applies: Exact preparation/population/endpoints only; applicability to selinexor independently assessed.
Abstract-only small acute preparation-specific trial; not selinexor or proof of safety in vulnerable patients.
Source 4: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 11, 2026
Population: Terminology.
selinexor is IN.
How this applies: Exact ingredient.
Not clinical evidence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Sources checked and article drafted. |
Article revision: 36d5124fb68fb7b9
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.